Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -90.55% is 126% below its 5-year average of -40.08%, near the low end of its 5-year range (-98.78%–-16.49%).
27.90% below its 12-month average of -70.80%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -28.20%.
RETURN ON ASSETS (ROA)
-90.55%
RETURN ON ASSETS (ROA) AVG TTM
-70.80%
RETURN ON ASSETS (ROA) AVG 3Y
-45.07%
RETURN ON ASSETS (ROA) AVG 5Y
-40.08%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-27.90%
CURRENT VS 3Y AVG
-100.90%
CURRENT VS 5Y AVG
-125.94%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.27%
median of 386 covered companies
CURRENT VS SECTOR MEDIAN
-289.04%
vs the sector median at left
Acumen Pharmaceuticals, Inc.
Market Cap
$153.84M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$152.45M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
Market Cap
$152.16M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$149.51M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
Market Cap
$162.82M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$142.49M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$142.11M
Return on Assets (ROA)
-36.33%
TTM Avg
-27.39%
3Y Avg
-256.74%
5Y Avg
-207.88%
Market Cap
$134.74M
Return on Assets (ROA)
-6.07%
TTM Avg
-5.08%
3Y Avg
-4.92%
5Y Avg
-1.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $153.84M | -90.55% | -70.80% | -45.07% | -40.08% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | -20.01% | -38.20% | -34.64% | -39.69% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -127.14% | -129.15% | -91.50% | -82.73% |
| Codexis, Inc. (CDXS)vs › | $149.51M | -25.59% | -36.78% | -35.70% | -27.05% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $162.82M | -50.30% | -131.74% | -92.52% | -67.08% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | 35.31% | -14.11% | -23.46% | -20.68% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -36.33% | -27.39% | -256.74% | -207.88% |
| Freenome, Inc. (FRNM)vs › | $137.29M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $134.74M | -6.07% | -5.08% | -4.92% | -1.70% |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | -38.62% | -32.73% | -28.05% | -37.08% |
ROA
-90.5%
ROE
-183.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -98.78% |
| 2024-12-31 | -42.82% |
| 2023-12-31 | -16.89% |
| 2022-12-31 | -21.80% |
| 2021-12-31 | -43.68% |
| 2020-12-31 | -16.49% |
| 2019-12-31 | -107.99% |
